

Aberrant Expression of Collagen Triple Helix Repeat Containing 1 in Human Solid Cancers

Liren Tang,^{1,2} Derek L. Dai,¹ Mingwan Su,^{1,2} Magdalena Martinka,³ Gang Li,¹ and Youwen Zhou^{1,2,4}

Abstract Purpose: The collagen triple helix repeat containing 1 (CTHRC1) is a promigratory protein first found to be expressed during rat tissue repair process. Recent preliminary results revealed CTHRC1 mRNA in melanoma and breast cancer. However, the full significance of CTHRC1 to human carcinogenesis remains unclear. This study is to further characterize the clinical and functional relevance of CTHRC1 in melanoma and other human solid cancers.

Experimental Design: First, semiquantitative immunohistochemistry analysis was done on 304 clinically annotated, paraffin-embedded biopsies representing different stages of melanoma progression. Then, short interfering RNA was used to inhibit expression of CTHRC1 protein for migration analysis on cultured melanoma cells. Finally, the CTHRC1 expression was surveyed in 310 samples representing 19 types of human solid cancers.

Results: In benign nevi and noninvasive melanoma biopsies, there was little CTHRC1 protein expression. In contrast, in invasive primary melanomas, there was a significant increase of CTHRC1 protein ($P < 0.01$, χ^2 test). There was a further increase of CTHRC1 protein in metastatic melanoma specimens compared with nonmetastatic lesions ($P < 0.01$, χ^2 test). In addition, inhibition of CTHRC1 expression resulted in decreased cell migration *in vitro*. Finally, transcription survey in 19 types of human solid cancers revealed aberrant CTHRC1 expression in 16 cancer types, especially cancers of the gastrointestinal tract, lung, breast, thyroid, ovarian, cervix, liver, and the pancreas.

Conclusions: Aberrant expression of CTHRC1 is widely present in human solid cancers and seems to be associated with cancer tissue invasion and metastasis. It potentially plays important functional roles in cancer progression, perhaps by increasing cancer cell migration.

Accounting for 3% of all cancers, malignant melanoma is one of the most aggressive cancers affecting humans (1, 2). Although early melanomas are curable with surgical excision, metastatic melanomas are associated with high mortality. Understanding the molecular details of melanoma may help developing new therapies. Gene expression profiling experiments have uncovered many genes potentially implicated in cancer invasion and metastasis (3–13). Some of the most striking and consistent changes are in molecules that regulate adhesion, extracellular matrix, and migration (3, 6, 7, 10–12, 14–16), including the osteopontin gene described from this

laboratory previously (12). Here, we describe a novel cancer-secreted extracellular protein, collagen triple helix repeat containing 1 (CTHRC1), which is aberrantly overexpressed in advanced melanoma cells.

Mammalian *CTHRC1* gene was first found in a screen for differentially expressed sequences in balloon-injured versus normal rat arteries. It was transiently expressed by fibroblasts of the remodeling adventitia and by smooth muscle cells of the neointima on injury in rat aorta (17). Enhanced expression of CTHRC1 in rat fibroblasts promotes cell migration and inhibits collagen I synthesis in these cells. Therefore, it has been suggested that CTHRC1 contributes to tissue repair in vascular remodeling in response to injury by limiting collagen matrix deposition and promoting cell migration. Accumulating evidence supports that tissue repair and carcinogenesis are tightly linked (18–20). To date, no investigation has addressed the roles of *CTHRC1* gene in cancer despite recent reports showing expression in stromal cells of breast cancer by *in situ* hybridization (21, 22). In this study, we examined the expression of CTHRC1 in melanoma and 19 other solid cancer types in humans and investigated its functional role in cancer using melanoma cells as the experimental system.

Authors' Affiliations: ¹Department of Dermatology and Skin Science and ²Chiang Genomics Centre, Laboratory of Predictive Medicine and Therapeutics, Vancouver Coastal Health Research Institute, and British Columbia Cancer Agency, ³Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada, and ⁴Institute of Dermatology, Anhui Medical University, Hefei, China
Received 1/6/06; revised 3/13/06; accepted 4/7/06.

Grant support: Canadian Chinese Help Care Society (YZ), Canadian Dermatology Foundation (Y. Zhou and L. Tang), Canada Foundation for Innovation (Y. Zhou), and Canadian Institutes of Health Research (Y. Zhou).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Youwen Zhou, Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E8. Phone: 604-875-4747; Fax: 604-873-9919; E-mail: ywzhou@interchange.ubc.ca.

©2006 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-06-0030

Materials and Methods

Melanoma and nevi biopsies and RNA preparation. Metastatic melanoma nodules and benign nevi were obtained from patients

with metastatic melanoma, with informed consent as approved by the University of British Columbia Clinical Ethics Board (Vancouver, British Columbia, Canada). The biopsies were collected as described previously (12). Briefly, biopsies were placed in the centers of the lesions and each lesion was sectioned into two equal parts. One part was formalin fixed and examined histologically for diagnostic confirmation and for estimation of melanoma/melanocyte content (at least 80%). The other part was immediately frozen in liquid nitrogen. The freshly frozen specimens were extracted for total RNA using Trizol protocol (Invitrogen, Burlington, Ontario, Canada) according to the manufacturer's instructions.

The formalin-fixed, paraffin-embedded archival biopsies used for immunohistochemistry were obtained from the archival collection of the Department of Pathology, Vancouver General Hospital (Vancouver, British Columbia, Canada).

Quantitative PCR. The cDNA synthesis reaction was done using 1 μ g total RNA for each sample using cDNA SuperScript First-Strand Synthesis System (Invitrogen). A portion of the resultant cDNA equivalent to 4 ng total RNA was used for quantitative real-time reverse transcription-PCR using the DNA Engine Opticon System (MJ Research, Waltham, MA). The primer sequences for the genes tested include the following: *CTHRC1*, 5'-TCATCGCACTTCTCTGTGGA-3' (forward) and 5'-GCCAACCCAGATAGCAACATC-3' (reverse); *S-100b*, 5'-ATCC-GAACTCAAGGAGCTCATC-3' (forward) and 5'-CGTCTTCATCATTGTC-CAGTGT-3' (reverse); *tyrosinase*, 5'-TTCTTCTCCTCTTGGCAGATTG-3' (forward) and 5'-TTCCAGGATTACGCCGTAAG-3' (reverse); *tyrosinase-related protein 1*, 5'-GGAACACITTTGTAACAGCACCG-3' (forward) and 5'-ACTGAGCGACATCCTGTGGTT-3' (reverse); and *glyceraldehyde-3-phosphate dehydrogenase*, 5'-AAGATCATCAGCAATGCCTCC-3' (forward) and 5'-TGGACTGTGGTCATGCCTT-3' (reverse). The PCRs were done in triplicates in a volume of 20 μ L using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). The amplification conditions were 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The cycle number of threshold (C_T) was recorded for each reaction. The C_T value of *CTHRC1* was normalized to that of glyceraldehyde-3-phosphate dehydrogenase of the same sample. The expression intensity of each gene in metastatic melanoma biopsies was expressed as fold changes over the average of nevus samples.

Antibody production and Western blotting. A polyclonal antibody was generated in the laboratory by immunizing two rabbits with a synthetic peptide (NH₂-CSRHIEELPK-COOH) from the COOH terminal of *CTHRC1* protein. The immune sera were affinity purified using the peptide with assistance of Immunochem Biopharm, Inc. (Burnaby, British Columbia, Canada). The purified antibody was stored at 1 mg/mL and used for Western blotting and immunohistochemistry staining.

For protein extraction, cultured cells were directly lysed in radio-immunoprecipitation assay buffer (PBS, 0.1% SDS, 1% NP40, 0.5% sodium deoxycholate). Protein concentration was measured with the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA). Total proteins (15 μ g) from cultured cells were subjected to 12% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Bio-Rad). After blocking in 5% nonfat milk in TBS [10 mmol/L Tris (pH 7.4), 150 mmol/L NaCl], the membrane was probed with anti-*CTHRC1* polyclonal antibody at 750 ng/mL in 3% bovine serum albumin in PBS. The secondary antibody was goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The signals were detected by enhanced chemiluminescence detection (Amersham Biosciences, Baie d'Urfe, Quebec, Canada). The anti- β -actin mouse monoclonal antibody (Sigma, St. Louis, MO) was used to reprobe the filter for monitoring the protein loading from each sample. The secondary goat anti-mouse antibody conjugated to horseradish peroxidase was also from Santa Cruz Biotechnology.

Immunohistochemistry. *CTHRC1* protein expression was analyzed by immunohistochemistry on paraffin-embedded clinical biopsies. The samples used for this study consisted of both 4- μ m tissue sections from

tissue microarrays containing multiple tumor biopsies ($n = 218$) and 4- μ m tissue sections from individually embedded tumor biopsies ($n = 86$). The staining procedure was the same for both types of sections and was described previously (12). The antibody used was a polyclonal antibody against the COOH terminal of the *CTHRC1* protein and verified to be specific using bacterial and mammalian cell-expressed *CTHRC1* protein on Western blotting. The concentration used was 4 μ g/mL. To locate melanocyte-derived cells, a polyclonal anti-S-100 antibody (DAKO Corp., Carpinteria, CA) was used on adjacent sections. The biotin-conjugated secondary antibody and streptavidin-horseradish peroxidase conjugates (LSAB+System, horseradish peroxidase) were purchased from DAKO. The visualization of the staining was achieved using DAKO Liquid 3,3'-Diaminobenzidine Substrate-Chromogen System. Normal rabbit serum at the same concentration was used on adjacent tissue sections as negative control.

Construction and clinical annotation of melanoma tissue microarrays were described previously (12, 23). The current melanoma tissue microarray consists of 16 human normal nevi, 204 primary melanomas, and 58 metastatic melanomas. Due to loss of biopsy cores or insufficient tumor cells present in the cores, 10 cases of normal nevi, 154 cases of primary melanomas, and 54 cases of melanoma metastases could be evaluated for *CTHRC1* staining. Combined with individual sections, a total of 304 samples were evaluated by immunohistochemistry.

To quantify the *CTHRC1* staining intensity, a three-point scoring scale was used: +1, no cells or <10% of cells stained; +2, majority of cells positive and moderately stained; and +3, ~100% cells positive and strongly stained (staining equivalent to or greater than that seen with S-100 antibody). Three independent investigators, including a dermatopathologist (M.M.), who were blinded of the clinical diagnosis of the sections and tumor thickness, assessed the stained slides, and a consensus score was reached for each sample. Because the staining results from individual sections were similar to that from the tissue microarray sections, the samples were combined in the final analysis. The χ^2 test was used to evaluate the statistical differences between the staining of different stages of melanocytic tumors. The same method was used to evaluate potential correlation between *CTHRC1* protein expression in primary melanoma samples and the clinical characteristic of the melanoma patients, such as tumor thickness and survival.

Normal melanocytes and melanoma cell lines. Two normal human epidermal melanocyte cell lines were isolated in the laboratory from neonatal foreskins as described (24), and one normal melanocyte cell line was purchased from Cascade BioScience, Inc. (Portland, OR). The melanocytes were cultured with melanocyte growth medium (Cascade BioScience) and maintained at 37°C with 5% CO₂. Cultures were provided with fresh medium thrice weekly, and melanocytes were used at passage 4 for RNA and protein extraction.

The melanoma cell lines were described previously (12). Cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum at 37°C in 5% CO₂. All the cultures were replenished with fresh medium 24 hours before harvesting for protein and RNA extraction.

RNA interference. The target short interfering RNA (siRNA) sequences of *CTHRC1* are as follows: 5'-CCCATTGAAGCTATAATTAT-3' (target 1) and 5'-CGCATCATTATTGAAGAATA-3' (target 2). The RNA duplexes were synthesized by Qiagen (Mississauga, Ontario, Canada). The control siRNA was purchased from Ambion (Houston, TX) as a 50 μ mol/L stock, and it is a RNA duplex synthesized from a random sequence. For siRNA transfection, melanoma cells were seeded 24 hours before the transfection in antibiotics-free DMEM containing 10% fetal bovine serum. The cells were transfected with 50 nmol/L siRNA using LipofectAMINE (Invitrogen) for 6 hours in antibiotics-free medium. Then, the medium was replaced with the normal DMEM with 10% fetal bovine serum containing proper antibiotics.

Cell migration assay. For migration assays, the siRNA-transfected cells after 24 hours were trypsinized and seeded on top of the insert membrane (0.8 μ m) of the Boyden chamber (BD Biosciences, Palo Alto, CA) in 0.1% fetal bovine serum in DMEM on a 24-well tissue culture

plate at 2.5×10^4 per well. The bottom of the chamber was filled with 10% fetal bovine serum-DMEM as chemoattractants. The cells were harvested at 24 hours. The cells on the top side of the membrane were removed by scrapping with cotton swap thrice. The cells that migrated to the other side of the membrane were washed with PBS twice and fixed with 4% formaldehyde in PBS for 30 minutes and then stained with 0.1% toluidine blue in PBS. After washing in water thrice, the membranes were briefly air dried and mounted on a glass slide and the cell number was counted under an inverted microscope. Ten fields of each membrane were counted, and the average for each sample was calculated. The assay was repeated thrice.

CTHRC1 expression in cancer cDNA arrays. A PCR-generated CTHRC1 cDNA fragment (forward primer, 5'-GCCAATGGCATTCCGGGTAC-3'; reverse primer, 5'-TGTGAAATCACACITTTGGTCTG-3') was ^{32}P labeled using the ready-to-go DNA-labeling beads (Amersham Biosciences). A membrane containing 155 pairs of tumors and their matching normal control cDNAs (Cancer Profiling Array II, BD Biosciences) was probed with the labeled CTHRC1 fragment at 68°C according to the manufacturer's instruction. The membrane was exposed to the film at -70°C, and the film was developed after 12 hours. A cDNA fragment of the control housekeeping gene ubiquitin provided by BD Biosciences was rehybridized to the stripped membrane and developed after 1-hour exposure. The signal intensity for each tumor-normal tissue pairs was obtained using GenePix Pro 4.1 software (Axon Instrument, Sunnyvale, CA) for analyzing autoradiography images of CTHRC1 hybridization. The CTHRC1 signal intensity was normalized to that of ubiquitin of the same sample. The ratio of tumor over normal control tissues was obtained from each paired sample.

Results

Identification of a novel cancer-associated gene, CTHRC1, in melanoma. In an attempt to explore differentially expressed genes between normal benign nevi and metastatic melanomas, we did DNA microarray analysis representing >21,000 genes comparing the normal nevi and metastatic melanoma nodules from the same patients (12). Several genes were shown to be overexpressed in metastatic melanocytes compared with the benign melanocytes, including osteopontin, which subsequently was found to be associated with melanoma invasion (12). Another melanoma differentially expressed gene identified is *CTHRC1*. This gene was highly overexpressed in metastatic melanomas but barely detectable in normal nevi. Quantitative reverse transcription-PCR analysis confirmed the elevated expression of *CTHRC1* in metastatic melanoma specimens ($n = 7$) when compared with normal nevi samples from 14 patients (Fig. 1). On average, metastatic specimens exhibited eight times more expression of *CTHRC1* mRNA compared with the normal nevi of similar melanocyte content (~80% for both metastatic melanoma nodules and benign i.d. nevi). The melanocytic marker S-100 was similarly present in the normal nevi and metastatic melanoma nodules, confirming that the differential expression of *CTHRC1* was not due to unequal melanocyte content. In addition, the metastatic melanoma nodules expressed less melanocyte differentiation markers, such as tyrosinase and tyrosinase-related protein 1, which frequently are lost during melanoma progression (Fig. 1; ref. 25).

On Western blotting, no *CTHRC1* expression was detected from three melanocyte cultures generated from different sources, whereas *CTHRC1* was easily detected from melanoma cell lines (Fig. 2). A major polypeptide band of ~25 kDa on




Fig. 1. CTHRC1 mRNA expression in normal nevi and metastatic melanoma nodules by quantitative reverse transcription-PCR. The expression intensity of each gene in metastatic melanoma biopsies (MM; $n = 7$; white columns) and normal nevi (NN; $n = 14$; black columns) was expressed as fold changes over the average of nevus samples. All values were normalized according to the glyceraldehyde-3-phosphate dehydrogenase levels.

Western blots was detected. This corresponds to the expected size of the human *CTHRC1* and was verified by transfecting expression vectors, directing the synthesis of *CTHRC1* into cultured mammalian cells (data not shown).

CTHRC1 protein expression is correlated with melanoma invasion and metastasis. Using immunohistochemistry staining, the *CTHRC1* protein was in melanoma cells of primary and metastatic melanoma biopsies. In contrast, no significant expression was present in benign nevi or noninvasive melanoma *in situ* cells (Fig. 3). The specificity of *CTHRC1* antibody staining of melanocytic cells in immunohistochemistry was shown using S-100 antibody on adjacent sections. Using a three-point staining intensity scale, the relative expression of *CTHRC1* protein in a spectrum of melanocytic tumors was quantified, combining results from 304 clinical specimens (Fig. 3B). The *CTHRC1* protein expression was weak or absent in benign nevi (normal nevi) and in noninvasive melanocytic tumors (melanoma *in situ*). In contrast, in melanoma samples that have invaded into the dermis (invasive primary melanomas), a dramatic increase of *CTHRC1* expression was present, with ~70% of tumors showing moderate to strong expression. The difference between benign nevi, noninvasive melanoma, and invasive primary melanoma was highly significant ($P < 0.001$, χ^2 test). Further increase of *CTHRC1* protein expression was observed in samples of metastatic melanoma, with >80% samples stained moderately to strongly. The difference between primary invasive melanoma and metastatic melanoma is also statistically significant ($P < 0.01$, χ^2 test).

Because the expression in primary melanoma was nonuniform, an attempt was made to correlate with patient's clinical characteristics, such as tumor thickness, 5-year disease-free survival, and overall survival. However, no significant correlation was identified (data not shown).

CTHRC1 promotes melanoma cell migration. To examine the functional roles of *CTHRC1* overexpression in melanoma cells, cultured KZ-28 melanoma cells were transfected with two siRNA duplexes against *CTHRC1*. As shown in Fig. 4A and B, both *CTHRC1* siRNA oligos effectively blocked *CTHRC1* expression at both mRNA and protein levels in KZ-28 cells.

Similar results were observed in another metastatic melanoma cell line, MMRU (data not shown). Because rat fibroblasts overexpressing CTHRC1 enhanced cell migration (17), we hypothesized that CTHRC1 will do the same for melanoma cells. The effect of CTHRC1 reduction on the migratory behaviors of melanoma cells was tested using Boyden chamber. At 24 hours, there was a 50% reduction of cell migration in the CTHRC1 "knockdown" cells compared with cells transfected with the control, nonspecific siRNA. At 48 hours, the reduction of migration by the CTHRC1 knockdown cells was further enhanced (Fig. 4C). Both CTHRC1 siRNA sequences had similar effects. The CTHRC1 siRNA2 was used in Fig. 4.

CTHRC1 expression is aberrantly up-regulated in the majority of human solid cancers. There is little information on the expression of this newly characterized human gene in human cancers. The only reports to date were on the transcript expression of CTHRC1 in breast cancer stromal cells using DNA microarrays and *in situ* hybridization (21, 22). To explore the expression of CTHRC1 in other tumor types, we used a CTHRC1-specific gene probe to hybridize to a membrane that contained 310 cDNA samples derived from clinical tumor biopsies from 155 cancer patients, each with one tumor biopsy and one match normal tissue (Cancer Profiling Array II). Nineteen types of human solid cancers were represented on this membrane. CTHRC1 expression was dramatically and aberrantly up-regulated in the vast majority of human cancers compared with the corresponding normal tissues (Fig. 5A). Especially, in the cancers of rectum, small intestine, colon, liver, lung, ovary, breast, thyroid gland, and cervix, almost all the tumor samples expressed more CTHRC1 mRNA compared with their normal control samples (Fig. 5A and B). Among the 10 skin cancers and their normal controls included on the membrane, 5 of 7 melanomas expressed more CTHRC1 mRNA than normal skin, whereas the 3 squamous cell carcinomas expressed less CTHRC1 than normal skin. The tumors of testis, prostate, and trachea showed no significant CTHRC1 expression changes compared with their normal controls.

Discussion

The current study describes the aberrant expression of the novel cancer-associated gene *CTHRC1* in melanoma and many other human solid cancers and investigated the potential roles




Fig. 2. Protein expression of CTHRC1 in cultured melanocytes and melanoma cell lines by Western blotting analysis. Protein extracts from three normal melanocyte cultures (HMEC1-3) and three melanoma cell lines (KZ-28, MMRU, and PMWK) were probed with anti-CTHRC1 antibody and re-probed with β -actin after stripping. A major protein band corresponding to 25 kDa was recognized from melanoma cells. No CTHRC1 proteins were detected from any of the normal melanocytes.




Fig. 3. Immunohistochemistry analysis of melanoma tissues by anti-CTHRC1 antibody. **A**, immunohistochemistry detection of CTHRC1 protein. Melanoma *in situ* (MIS) had no anti-CTHRC1 activity, primary melanoma (PM) was intermediately positive, whereas metastatic melanoma (MM) samples were strongly stained. **B**, semiquantitative analysis. The signal intensity with CTHRC1 immunostaining was divided into three categories (1, 2, and 3) as described in Materials and Methods. The percentages of positive staining for each tumor stage in each intensity category were plotted. Statistically significant difference between normal nevi, melanoma *in situ*, and primary melanoma (*) and between primary and metastatic melanomas (**) were observed ($P < 0.01$, χ^2 test).

played by *CTHRC1* in cancer cells. There is little information previously known about this gene in human cells. The overall domain structure is the same as that of rat and mouse, containing an NH_2 -terminal signal peptide for extracellular secretion, a short collagen triple helix repeat of 36 amino acids, and a COOH -terminal globular domain (17). There is a 92% amino acid sequence identity between human and rat CTHRC1 proteins (data not shown).

The possible involvement of CTHRC1 in human carcinogenesis was first suggested by a recent report that some stromal cells in breast cancer expressed CTHRC1 mRNA by cDNA microarray analysis and *in situ* hybridization (21). The results presented here suggest that melanoma cells aberrantly express both CTHRC1 mRNA and CTHRC1 protein (Figs. 1-3). Although it cannot be excluded that stromal cells in melanoma

tissues also express this protein, the main source of CTHRC1 protein in melanoma tissues is, however, likely to be melanoma cells because the staining was mainly in S-100 staining cells of the tissue sections (Fig. 3) and that pure cultures of melanoma cell lines expressed this protein using Western blotting analysis (Fig. 2).

The functional significance of CTHRC1 expression in melanoma progression is unknown. The observation that it is absent in noninvasive stages of melanoma (melanoma *in situ*) and greatly increased in samples of invasive primary melanoma suggests that it may be important in tumor cell invasion into the dermal tissue. In addition, a further statistically significant increase was observed in metastatic melanoma, suggesting a possible role at this critical step of melanoma

progression as well. Further experiments are required to verify these associations.

The exact molecular role played by CTHRC1 in melanoma cells is also unknown. However, because in rat cells, the increased expression caused the fibroblast cells to have increased migration (17), it might be possible that CTHRC1 has a promigratory role in melanoma cells. Indeed, when CTHRC1 in melanoma cells was inhibited by siRNA, there was a significant reduction in cell migration (Fig. 4). Because tissue invasion and metastasis both involve cancer cell migration, it is possible that CTHRC1 contributes to these steps by increasing tumor cell migration.

At present, the mechanism of CTHRC1 aberrant expression in metastatic melanoma and the molecular mechanisms of CTHRC1 promigratory function are not clear. In murine NIH3T3 cells, CTHRC1 was induced by transforming growth factor- β and bone morphogenetic protein-4 (17). Melanoma cells produce transforming growth factor- β and bone morphogenetic protein-4, and expression of both directly correlates with the advanced depth of tumor invasion (26–30). Sequence analysis of the CTHRC1 promoter region reveals a binding site of SMAD, which is responsive to transforming growth factor- β /bone morphogenetic protein regulation. Therefore, it is possible that up-regulation of CTHRC1 in melanoma cells is due to activation of transforming growth factor- β /bone morphogenetic protein-4 pathway.

It is not clear about how CTHRC1 regulates melanoma cell migration. Like osteopontin, another secreted extracellular protein found to be overexpressed by melanoma cells from our laboratory (12), CTHRC1 may regulate cell migration as a bridging and/or cell adhesion protein. Consistent with this, CTHRC1 and osteopontin have been found to be colocalized in calcified atherosclerotic plaque particularly at the calcifying front (17, 31). To date, a direct interaction between CTHRC1 and osteopontin has not been studied. It is also possible that CTHRC1 produced by melanoma cells promotes tumor invasion by regulating the surrounding microenvironment, most likely the stromal cells and extracellular matrix. Numerous reports showed that the tumor microenvironment is pivotal for cancer cell growth/survival, invasion, and metastasis (32–34). Crucial stromal cells in the environment are fibroblasts (also termed cancer-associated fibroblasts) that are located in the vicinity of the neoplastic cells. We have detected CTHRC1 protein from conditioned medium of cultured melanoma cells.⁵ Because mouse fibroblasts almost completely shut down collagen I gene transcription in the presence of increased CTHRC1 protein (17), it is possible that the secreted form of human CTHRC1 overproduced by melanoma cells acts on stromal fibroblasts to decrease synthesis of extracellular matrix components, such as collagen I, and thus prepares the extracellular environment for tumor invasion, survival, and metastasis.

Human tumor cDNA array analysis showed that, with the exception of testis and prostate cancers, the CTHRC1 aberrant expression seems to be widely present in solid human cancers. Because CTHRC1 seems to regulate melanoma cell migration, it may also be important for most of the other solid cancers surveyed in this study.




Fig. 4. Knockdown of CTHRC1 expression by siRNA reduced melanoma cell migration. **A**, inhibition of CTHRC1 mRNA expression by siRNA in KZ-28 melanoma cells. Cultured KZ-28 cells were treated with synthetic control or two CTHRC1-specific siRNA oligos for 24 hours, and the cells were harvested for RNA extraction and for quantitative PCR analysis with primers designed from CTHRC1 and glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) cDNA. Both siRNAs efficiently blocked CTHRC1 mRNA expression, whereas the levels of glyceraldehyde-3-phosphate dehydrogenase mRNA did not change. **B**, inhibition of CTHRC1 protein expression by siRNA in KZ-28 melanoma cells. Cultured KZ-28 cells were treated the same way as above and harvested for Western blotting with anti-CTHRC1 antibody. Specific and efficient inhibition was achieved using both CTHRC1-specific siRNA oligos. β -Actin levels were not altered. **C**, reduction of migrated melanoma cells by CTHRC1 siRNA. siRNA-transfected KZ-28 cells were seeded on top of Boyden chamber. The cells that migrated to the other side of the membrane were counted at 24 and 48 hours. The average number of cells migrated was compared between the control and CTHRC1 siRNA-transfected cells. Significant differences between control siRNA-transfected and CTHRC1 siRNA2-transfected cells were observed ($P < 0.01$, Student's *t* test).

⁵ Unpublished data.




Fig. 5. CTHRC1 expression in human solid cancers. The CTHRC1 cDNA fragment was hybridized to Cancer Profiling Array II, representing 19 human cancers and 10 cancer cell lines. Each tumor sample (*T*) is matched with its own normal control tissue (*N*). The same array was stripped and reprobed with the housekeeping ubiquitin gene fragment. *A*, image probed with CTHRC1 fragment. *B*, image of ubiquitin expression on the same membrane.

In summary, we have found that CTHRC1 aberrant up-regulation is present in the vast majority of human cancers. In addition, this up-regulation seems to be correlated with cancer progression steps, such as tumor invasion and metastasis.

CTHRC1 may be functionally important in these steps by increasing tumor cell migration. Targeting CTHRC1 may represent an attractive approach for developing a wide-spectrum cancer therapy for a variety of human cancers.

References

- Houghton AN, Polsky D. Focus on melanoma. *Cancer Cell* 2002;2:275–8.
- Gaudette LA, Gao RN. Changing trends in melanoma incidence and mortality. *Health Rep* 1998;10:29–41 (Eng); 33–46 (Fre).
- Bar-Eli M. Molecular mechanisms of melanoma metastasis. *J Cell Physiol* 1997;173:275–8.
- Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin β_4 in tumor metastasis and angiogenesis. *J Natl Cancer Inst* 2003;95:1674–80.
- Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. *Nature* 2000;406:532–5.
- Gutgemann A, Golob M, Muller S, Buettner R, Bosserhoff AK. Isolation of invasion-associated cDNAs in melanoma. *Arch Dermatol Res* 2001; 293:283–90.
- Huntington JT, Shields JM, Der CJ, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. *J Biol Chem* 2004;279:33168–76.
- Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sefti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. *Mol Cell Biol* 2004;24:5565–76.
- Kurschat P, Mauch C. Mechanisms of metastasis. *Clin Exp Dermatol* 2000;25:482–9.
- McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. *Cancer Biol Ther* 2002;1:459–65.
- Seftor RE, Seftor EA, Gehlsen KR, et al. Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion. *Proc Natl Acad Sci U S A* 1992;89:1557–61.
- Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. *J Invest Dermatol* 2005;124:1044–52.
- Hussein MR. Genetic pathways to melanoma tumorigenesis. *J Clin Pathol* 2004;57:797–801.
- Koistinen P, Ahonen M, Kahari VM, Heino J. α_v integrin promotes *in vitro* and *in vivo* survival of cells in metastatic melanoma. *Int J Cancer* 2004;112:61–70.

15. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. *Am J Pathol* 2004;164:193–203.
16. Hendrix MJ, SefTOR EA, Hess AR, SefTOR RE. Molecular plasticity of human melanoma cells. *Oncogene* 2003;22:3070–5.
17. Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. *Circ Res* 2005;96:261–8.
18. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med* 1986;315:1650–9.
19. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. *Nature* 2004;432:324–31.
20. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860–7.
21. Allinen M, Beroukhi R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell* 2004;6:17–32.
22. West RB, Nuyten DS, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. *PLoS Biol* 2005;3:e187.
23. Dai DL, Makretsov N, Campos EI, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. *Clin Cancer Res* 2003;9:4409–14.
24. Gilchrist BA, Vrabel MA, Flynn E, Szabo G. Selective cultivation of human melanocytes from newborn and adult epidermis. *J Invest Dermatol* 1984;83:370–6.
25. Hendrix MJ, SefTOR EA, Hess AR, SefTOR RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. *Nat Rev Cancer* 2003;3:411–21.
26. Teti A, De Giorgi A, Spinella MT, et al. Transforming growth factor- β enhances adhesion of melanoma cells to the endothelium *in vitro*. *Int J Cancer* 1997;72:1013–20.
27. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor- β 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. *Am J Pathol* 1994;145:97–104.
28. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)- β 1 and TGF- β 2 in patients with disseminated malignant melanoma. *Br J Cancer* 1998;77:1492–4.
29. Janji B, Melchior C, Gouon V, Vallar L, Kieffer N. Autocrine TGF- β -regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. *Int J Cancer* 1999;83:255–62.
30. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. *Cancer Res* 2005;65:448–56.
31. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. *J Clin Invest* 1994;94:1597–604.
32. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? *Lung Cancer* 2004;45 Suppl 2: S163–75.
33. Kataoka H, Tanaka H, Nagaike K, Uchiyama S, Itoh H. Role of cancer cell-stroma interaction in invasive growth of cancer cells. *Hum Cell* 2003;16:1–14.
34. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. *Nature* 2004;432:332–7.